The reduced expression of the CDKN1C gene in carcinoma samples (PTC and FTC) (group 2) and FTC samples (group 5) compared to normal and benign samples (group 1) in both the PCR Array and RT-qPCR analyses, as well as in FTC samples compared to PTC group samples in the RT-qPCR analysis, indicates the diagnostic potential of this gene in differentiating FTC samples from other thyroid pathologies. This evidence concerns the gene CDKN1C and carcinoma.